Rankings
▼
Calendar
CAI Q3 2025 Earnings — Caris Life Sciences, Inc. Revenue & Financial Results | Market Cap Arena
CAI
Caris Life Sciences, Inc.
$5B
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$217M
Gross Profit
$148M
68.0% margin
Operating Income
$33M
15.1% margin
Net Income
$24M
11.2% margin
EPS (Diluted)
$0.08
QoQ Revenue Growth
+19.5%
Cash Flow
Operating Cash Flow
$62M
Free Cash Flow
$55M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$985M
Total Liabilities
$506M
Stockholders' Equity
$478M
Cash & Equivalents
$753M
Revenue Segments
Pharma Research And Development Services
$9M
100%
Geographic Segments
UNITED STATES
$214M
98%
Non-US
$3M
2%
← FY 2025
All Quarters
Q4 2025 →
